MOSAPRIDE CITRATE DIHYDRATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H25ClFN3O3.C6H8O7.2H2O
Molecular Weight	650.047
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MOSAPRIDE CITRATE DIHYDRATE

Structure Search

SMILES

O.O.OC(=O)CC(O)(CC(O)=O)C(O)=O.CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2

InChI

InChIKey=KVKIQHMTGSGTFO-UHFFFAOYSA-N

InChI=1S/C21H25ClFN3O3.C6H8O7.2H2O/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10;;/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);2*1H2

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C21H25ClFN3O3
Molecular Weight	421.893
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34357 | https://www.drugs.com/international/mosapride.html | https://www.ncbi.nlm.nih.gov/pubmed/9399969

Mosapride is a gastroprokinetic agent, a 5-HT4 receptor agonist and 5-HT3 receptor antagonist exhibiting no activity at dopamine D2, 5-HT1 and 5-HT2 receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility. It is usually used to treat heartburn, nausea and vomiting caused by chronic gastritis. Mosapride is approved and marketed in the countires of Asia and Latin America.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 4 (5-HT4) receptor 38 Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9399969 \| https://www.ncbi.nlm.nih.gov/pubmed/10646498 \| http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=242	Agonist 2752		6.2 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastritis 46 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22541755 https://www.ncbi.nlm.nih.gov/pubmed/18457463	Primary		Approved 8583	MOSAPRIDE CITRATE TABLETS 2.5mg "DSEP" Approved Use MOSAPRIDE CITRATE TABLETS 2.5mg "DSEP" are usually used to treat heartburn, nausea and vomiting caused by chronic gastritis.

C_max

Value	Dose	Co-administered	Analyte	Population
26.4 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.4 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
30.7 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	5 mg 1 times / 3 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
39.3 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	5 mg 1 times / 3 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
62.9 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	10 mg 1 times / 3 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
95.8 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	10 mg 1 times / 3 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
113.6 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	20 mg 1 times / 3 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
154.6 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	20 mg 1 times / 3 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.5 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.7 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
47.8 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	10 mg 1 times / 2 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
104.7 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	10 mg 1 times / 2 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
116.1 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
272.6 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
154.2 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
265.3 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.41 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34837418/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: PANCRELIPASE	PANCRELIPASE	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
30.7 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
63.6 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
182.2 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
312.3 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
29.1 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
130.9 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
46.7 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	5 mg 1 times / 3 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
152.1 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	5 mg 1 times / 3 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
96.5 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	10 mg 1 times / 3 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
346.8 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	10 mg 1 times / 3 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
161.2 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	20 mg 1 times / 3 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
554 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	20 mg 1 times / 3 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.5 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
131.1 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	5 mg 1 times / 2 hours multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
58 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	10 mg 1 times / 2 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
305.7 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	10 mg 1 times / 2 hours multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
150.3 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
848.8 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
154.6 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
913 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	20 mg 1 times / 2 hours multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: SODIUM SULFATE ANHYDROUS	SODIUM SULFATE ANHYDROUS	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56.53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34837418/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: PANCRELIPASE	PANCRELIPASE	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
67 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
170 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
380 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
699 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34837418/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: PANCRELIPASE	PANCRELIPASE	MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		MOSAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% REVIEW https://pubmed.ncbi.nlm.nih.gov/18457463/			MOSAPRIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
45 mg 1 times / day multiple, oral Higher than recommended Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16263322/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16263322/	Sources: https://pubmed.ncbi.nlm.nih.gov/16263322/
5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15719424/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15719424/	Disc. AE: Epigastric discomfort... AEs leading to discontinuation/dose reduction: Epigastric discomfort (7.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/15719424/
5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22004457/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22004457/	Disc. AE: Fatigue... AEs leading to discontinuation/dose reduction: Fatigue (0.36%) Sources: https://pubmed.ncbi.nlm.nih.gov/22004457/

AEs

AE	Significance	Dose	Population
Epigastric discomfort	7.1% Disc. AE	5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15719424/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15719424/
Fatigue	0.36% Disc. AE	5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22004457/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22004457/

PubMed

Title	Date	PubMed
Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ring-opened mosapride by UPLC-ESI-MS/MS.	2009-08-15	19362796
Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract.	2009-04	19220673
Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility.	2009-04	18723200
The plasticity of the defecation reflex pathway in the enteric nervous system of guinea pigs.	2009-02	19377268
Impaired gastric motility and its relationship to reflux symptoms in patients with nonerosive gastroesophageal reflux disease.	2009	19214661
Effect of mosapride on recovery of intestinal motility after hand-assisted laparoscopic colectomy for carcinoma.	2008-11	18584249
Choledochoscope manometry about different drugs on the Sphincter of Oddi.	2008-10-14	18855992
Validation of 13C-acetic acid breath test by measuring effects of loperamide, morphine, mosapride, and itopride on gastric emptying in mice.	2008-10	18827355
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.	2008-09	18482254
Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.	2008-08	18699977
Multiple system atrophy and impaired gallbladder emptying.	2008-07-15	18546330
Effects of mosapride citrate on patients after vagal nerve, lower esophageal sphincter, and pyloric sphincter-preserving nearly total gastrectomy reconstructed by jejunal J pouch interposition, and postoperative quality of life.	2008-07-11	18613449
The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.	2008-07	18415081
The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.	2008-07	18408918
Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro.	2008-06-30	18581598
The prokinetic effect of mosapride citrate on horse gastric emptying rates.	2008-06	18628607
Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.	2008-05	18028348
A new possibility for repairing the anal dysfunction by promoting regeneration of the reflex pathways in the enteric nervous system.	2008-04	18308859
5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs.	2008-04	18198343
Quantitative determination of domperidone in human plasma by ultraperformance liquid chromatography with electrospray ionization tandem mass spectrometry.	2008-04	18059046
Long-term Ultrasonographic Follow-up Study of Gastric Motility in Patients with Functional Dyspepsia.	2008-03	18385832
Effects of milnacipran on binge eating - a pilot study.	2008-02	18728825
The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro.	2008-02	17931343
Role of ion channel modifiers in reversal of morphine-induced gastrointestinal inertia by prokinetic agents in mice.	2008-01	18697573
High-performance liquid chromatography and thin-layer chromatography for the simultaneous quantitation of rabeprazole and mosapride in pharmaceutical products.	2008-01	18218182
Prokinetics influence the pharmacokinetics of rabeprazole.	2008	18948689
Efficacy of prokinetic agents in improving bowel preparation for colonoscopy.	2008	18577886
Mosapride in gastrointestinal disorders.	2008	18457463
Liquid chromatography-tandem mass spectrometric method for determination of mosapride citrate in equine tissues.	2007-10-15	17851144
Rapid effect of mosapride citrate, 5-HT4 receptor agonist, on fasting blood glucose in Type 2 diabetes patients.	2007-10-10	18413172
The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.	2007-10	17928736
Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials.	2007-10	17845684
Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy.	2007-10	17683491
Thermal care of functional dyspepsia based on bicarbonate-sulphate-calcium water: a sequential clinical trial.	2007-09	17965771
[Determination of mosapride in human plasma by high performance liquid chromatography tandem mass spectrometry].	2007-08	17944240
Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.	2007-03	17295758
Quantification of pseudoephedrine in human plasma by LC-MS/MS using mosapride as internal standard.	2007-03	17230461
Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard.	2007-02	17221908
Mosapride citrate prolongs survival in stroke patients with gastrostomy.	2007-01	17233710
Acid regurgitation associated with persistent cough after pulmonary resection: an observational study.	2006-11-14	17101061
Enhancement of the intrinsic defecation reflex by mosapride, a 5-HT4 agonist, in chronically lumbosacral denervated guinea pigs.	2006-10	17159330
[Effects of acute hypobaric hypoxia on gastric emptying and intestinal propulsion: experiment with rats].	2006-09-12	17156648
[Serotonin 5- HT4 receptor agonist (mosapride citrate)].	2006-08	16898619
The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers.	2006-04	16633098
Enantioselective determination of a gastroprokinetic drug using amylose tris-(3,5-dimethylphenylcarbamate) as a stationary phase by HPLC.	2006-02-13	16311003
Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry.	2006-02	16440196
Effects of mosapride citrate on patients after vagal nerve preserving distal gastrectomy reconstructed by interposition of a jejunal J pouch with a jejunal conduit for early gastric cancer.	2006-02	16425073
Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study.	2006	16969767
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.	2005-03	18360537
Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying.	2004-11-11	16389169

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 2 tablets (5 mg of mosapride citrate) at a time, 3 times a day, before or after meal.

Route of Administration: Oral

In Vitro Use Guide

Mosapride (1-10 uM) enhanced differentiation of neural networks in ES gut-like organ from mouse ES cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:36:47 GMT 2025` Edited by `admin` on `Mon Mar 31 19:36:47 GMT 2025`
Record UNII	73033I28Y6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOSAPRIDE CITRATE HYDRATE

Preferred Name

English

MOSAPRIDE CITRATE DIHYDRATE

Common Name

English

MOSAPRIDE CITRATE HYDRATE [JAN]

Common Name

English

BENZAMIDE, 4-AMINO-5-CHLORO-2-ETHOXY-N-((4-((4-FLUOROPHENYL)METHYL)-2-MORPHOLINYL)METHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1), DIHYDRATE

Common Name

English

BENZAMIDE, 4-AMINO-5-CHLORO-2-ETHOXY-N-((4-((4-FLUOROPHENYL)METHYL)-2-MORPHOLINYL)METHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE, HYDRATE (1:1:2)

Systematic Name

English

Code System Code Type Description

PUBCHEM

6918047